JP2016532713A - 肝臓ｘ受容体（ｌｘｒ）調節因子 - Google Patents

肝臓ｘ受容体（ｌｘｒ）調節因子 Download PDF

Info

Publication number
JP2016532713A
JP2016532713A JP2016540378A JP2016540378A JP2016532713A JP 2016532713 A JP2016532713 A JP 2016532713A JP 2016540378 A JP2016540378 A JP 2016540378A JP 2016540378 A JP2016540378 A JP 2016540378A JP 2016532713 A JP2016532713 A JP 2016532713A
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016540378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532713A5 (OSRAM
Inventor
ラジュ モーハン，
ラジュ モーハン，
Original Assignee
アレクサー セラピューティクス， インク．
アレクサー セラピューティクス， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクサー セラピューティクス， インク．, アレクサー セラピューティクス， インク． filed Critical アレクサー セラピューティクス， インク．
Publication of JP2016532713A publication Critical patent/JP2016532713A/ja
Publication of JP2016532713A5 publication Critical patent/JP2016532713A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2016540378A 2013-09-04 2014-09-04 肝臓ｘ受容体（ｌｘｒ）調節因子 Pending JP2016532713A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361873746P 2013-09-04 2013-09-04
US61/873,746 2013-09-04
PCT/US2014/054065 WO2015035027A1 (en) 2013-09-04 2014-09-04 Liver x receptor (lxr) modulators

Publications (2)

Publication Number Publication Date
JP2016532713A true JP2016532713A (ja) 2016-10-20
JP2016532713A5 JP2016532713A5 (OSRAM) 2017-10-12

Family

ID=52628920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540378A Pending JP2016532713A (ja) 2013-09-04 2014-09-04 肝臓ｘ受容体（ｌｘｒ）調節因子

Country Status (10)

Country Link
US (1) US9981913B2 (OSRAM)
EP (1) EP3041834A4 (OSRAM)
JP (1) JP2016532713A (OSRAM)
KR (1) KR20160048997A (OSRAM)
CN (1) CN105683176A (OSRAM)
CA (1) CA2923178A1 (OSRAM)
IL (1) IL244412A0 (OSRAM)
MX (1) MX2016002930A (OSRAM)
SG (1) SG11201601644RA (OSRAM)
WO (1) WO2015035027A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3441390A1 (en) 2012-03-02 2019-02-13 Ralexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
AU2014315280B2 (en) 2013-09-04 2019-01-24 Ellora Therapeutics, Inc. Liver X receptor (LXR) modulators
EP3124620B1 (en) * 2015-07-27 2018-08-08 Chanel Parfums Beauté Activators of uc.291 for use for improving skin barrier function and/or for preventing and/or attenuating skin ageing and/or for hydrating skin
CN111100071A (zh) * 2019-12-19 2020-05-05 西安近代化学研究所 一种合成2-氰基-5-芳基-1h-咪唑类化合物的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543970A (ja) * 2005-06-27 2008-12-04 エグゼリクシス， インコーポレイテッド ピラゾールベースのｌｘｒモジュレーター
JP2010512342A (ja) * 2006-12-08 2010-04-22 エグゼリクシス， インコーポレイテッド Ｌｘｒおよびｆｘｒのモジュレーター
WO2010075203A1 (en) * 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
WO2010096170A2 (en) * 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
WO2013130892A1 (en) * 2012-03-02 2013-09-06 Anayaderm, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072868A1 (en) 2000-09-18 2004-04-15 Collins Jon Loren Substitued aminopropoxyaryl derivatives useful as agonists for lxr
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2486651A1 (en) 2002-05-24 2003-12-04 Pharmacia Corporation Sulfone liver x-receptor modulators
US6900244B2 (en) 2002-05-24 2005-05-31 Pharmacia Corporation Anilino liver X-receptor modulators
EP1572660B1 (en) 2002-12-20 2011-01-26 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
US20060270628A1 (en) * 2003-04-29 2006-11-30 Jagattaran Das Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005113499A1 (ja) 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
AU2005271737A1 (en) 2004-08-03 2006-02-16 Wyeth Indazoles useful in treating cardiovascular diseases
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US7213797B2 (en) 2005-05-20 2007-05-08 Garland Jerome Gaskins Deck board straightener
CN101248049B (zh) 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 咪唑类lxr调节剂
AU2006290442B2 (en) 2005-09-16 2010-07-29 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis C
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
WO2007092065A2 (en) 2005-11-14 2007-08-16 Irm Llc Compounds and compositions as lxr modulators
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
MX2009012474A (es) 2007-05-18 2009-12-18 Wyeth Corp Compuestos de quinazolina.
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
CN103772299A (zh) 2007-08-13 2014-05-07 霍夫曼-拉罗奇有限公司 新型哌嗪酰胺衍生物
BRPI0821315A2 (pt) 2007-12-21 2019-09-24 Wyeth Llc compostos benzimidazol
BRPI0822237A2 (pt) 2007-12-21 2015-06-30 Wyeth Llc Compostos de imidazo [1,2-a] piridina
US20120015988A1 (en) 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
US8063088B2 (en) 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
JP2012508250A (ja) 2008-11-07 2012-04-05 ワイス・エルエルシー キノキサリン系のｌｘｒモジュレーター
EP2367801A1 (en) 2008-11-19 2011-09-28 Wyeth LLC Polar quinazolines as liver x receptors ( lxrs ) modulators
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
HRP20170194T1 (hr) 2009-05-28 2017-05-19 Exelixis Patent Company Llc Lxr modulatori
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
WO2012020820A1 (ja) 2010-08-11 2012-02-16 大正製薬株式会社 ヘテロアリール－ピラゾール誘導体
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
CN102584705B (zh) 2011-01-18 2015-05-13 中国中化股份有限公司 3-羟基-取代吡唑的制备方法
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
ES2765573T3 (es) 2012-08-13 2020-06-09 Univ Rockefeller Tratamiento y diagnóstico de melanoma
AU2014315280B2 (en) 2013-09-04 2019-01-24 Ellora Therapeutics, Inc. Liver X receptor (LXR) modulators

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543970A (ja) * 2005-06-27 2008-12-04 エグゼリクシス， インコーポレイテッド ピラゾールベースのｌｘｒモジュレーター
JP2008543971A (ja) * 2005-06-27 2008-12-04 エグゼリクシス， インコーポレイテッド イミダゾールに基づくｌｘｒモジュレーター
JP2010512342A (ja) * 2006-12-08 2010-04-22 エグゼリクシス， インコーポレイテッド Ｌｘｒおよびｆｘｒのモジュレーター
WO2010075203A1 (en) * 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
WO2010096170A2 (en) * 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
WO2013130892A1 (en) * 2012-03-02 2013-09-06 Anayaderm, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
JP2015512883A (ja) * 2012-03-02 2015-04-30 アナヤデルム， インク．Ａｎａｙａｄｅｒｍ， Ｉｎｃ． 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子

Also Published As

Publication number Publication date
SG11201601644RA (en) 2016-04-28
US20160214943A1 (en) 2016-07-28
KR20160048997A (ko) 2016-05-04
MX2016002930A (es) 2016-12-02
EP3041834A4 (en) 2017-01-18
CN105683176A (zh) 2016-06-15
EP3041834A1 (en) 2016-07-13
IL244412A0 (en) 2016-04-21
WO2015035027A1 (en) 2015-03-12
CA2923178A1 (en) 2015-03-12
US9981913B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
JP6800922B2 (ja) 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子
ES2928904T3 (es) Moduladores de ROR-gamma
US9981913B2 (en) Liver X receptor (LXR) modulators
JP6821737B2 (ja) 肝臓ｘ受容体（ｌｘｒ）のモジュレーター
AU2014315206A1 (en) Liver X receptor (LXR) modulators
HK1206030B (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
HK1226729A1 (en) Liver x receptor (lxr) modulators
HK1226729B (en) Liver x receptor (lxr) modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190205